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The emerging Role of NeTs in 
venous Thrombosis and 
immunothrombosis
Andrew S. Kimball, Andrea T. Obi, Jose A. Diaz and Peter K. Henke*
Section of Vascular Surgery, Conrad Jobst Vascular Research Laboratories, Department of Surgery, University of Michigan, 
Ann Arbor, MI, USA
Venous thrombosis (VT), a leading cause of morbidity and mortality worldwide, has
recently been linked to neutrophil activation and release of neutrophil extracellular traps 
(NETs) via a process called NETosis. The use of various in vivo thrombosis models and 
genetically modified mice has more precisely defined the exact role of NETosis in the 
pathogenesis of VT. Translational large animal VT models and human studies have con-
firmed the presence of NETs in pathologic VT. Activation of neutrophils, with subsequent 
NETosis, has also been linked to acute infection. This innate immune response, while 
effective for bacterial clearance from the host by formation of an intravascular bactericidal 
“net,” also triggers thrombosis. Intravascular thrombosis related to such innate immune 
mechanisms has been coined immunothrombosis. Dysregulated immunothrombosis has 
been proposed as a mechanism of pathologic micro- and macrovascular thrombosis in 
sepsis and autoimmune disease. In this focused review, we will address the dual role of 
NETs in the pathogenesis of VT and immunothrombosis.
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iNTRODUCTiON
Neutrophils (PMNs) have frequently been touted as the pawns of the immune system. As our 
knowledge of immune system grows and as our techniques for evaluating dynamic cell populations 
improve – we are learning that this could not be further from the truth. While a PMNs principle 
function remains as a key player in the front line of innate immunity and host defense against bac-
teria, they are proving to have a multifaceted role in coagulation and have also been implicated as 
major contributors in the pathophysiology of many systemic illnesses.
Until the early 2000s, the associations between PMN activation and systemic disease had not 
been well understood; but in March of 2004, Brinkmann et  al. published a landmark study in 
Science (1), where they described a fragile fibrillar material extruded from PMNs in the presence 
of lipopolysaccharide (LPS) by transmission electron microscopy (TEM). In actuality, these fragile 
fibers were decondensed chromatin and DNA, as they stained strongly for DNA and histones, they 
were resistant to proteases, and they disappeared upon instillation of DNase. Bacteria were found to 
colocalize with the extruded DNA in vivo in a rabbit model of shigellosis and in human specimens 
of acute appendicitis. In summation, they demonstrated that these large webs of DNA trap bacteria 
and allow adjacent or connected PMNs to drive bactericidal activity with proteases and reactive 
oxygen species. Brinkmann et al. coined these nuclear extrusions “neutrophil extracellular traps” 
or NETs.
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Since that time, there has been a flurry of exciting new work 
in the field of NET formation (NETosis). NETosis has been 
demonstrated to be a distinct form of cell death outside of 
necrosis and apoptosis (2). Also, more interestingly, NETs have 
been indicted in the pathophysiology of many systemic diseases, 
including venous thrombosis (VT) (3), sepsis (4, 5), trauma (6), 
cancer-related thrombosis (7), and autoimmune diseases (8–12). 
Despite the apparent widespread influence of NETs on disease, 
there remains a common theme throughout that NETs drive 
micro- or macrovascular thrombosis leading to ischemia and 
further injury (13, 14).
In this article, we will review the role of NETs in pathologic 
thrombosis. Specifically, we will review the findings of NET 
pathophysiology in murine models of VT, NETs in primate mod-
els and human studies of VT, and NETs in immunothrombosis.
NeTs iN MURiNe vT MODeLS
Murine models have been essential to our understanding of the 
role of NETosis in the pathophysiology of thrombosis. PMNs 
were first shown to be essential for immune-mediated micro-
vascular thrombosis in a murine model of glomerulonephritis, 
in which CD11b−/− or PMN-depleted mice were resistant to 
glomeruli thrombosis and renal failure (15). At that time, it was 
not widely recognized that NETs contributed to thrombosis; 
however, this changed in 2010, when Fuchs et  al. showed that 
NETs caused platelet adhesion, activation, and aggregation (3). 
Stimulation of platelets with purified histones was sufficient for 
aggregation, and interestingly, DNase and heparin dismantled the 
NET scaffold and prevented thrombus formation. Brill et al. later 
demonstrated that NETs are principle effectors in an IVC stenosis 
model (16). In mice with uninterrupted IVC side-branches, levels 
of extracellular DNA increased in plasma 6  h after thrombus 
initiation. Citrullinated histone H3 (CitH3), an element of NETs’ 
structure, was present in thrombi and was frequently associated 
with the Gr-1 antigen. Furthermore, immunofluorescent stain-
ing of thrombi showed proximity of extracellular CitH3 and von 
Willebrand factor (vWF), a platelet adhesion molecule crucial for 
thrombus development in this particular model.
Neutrophils, monocytes, and NETs have also been found to 
affect the clotting cascade in murine models of thrombosis (17–
20). For example, myeloid cells roll along the venous endothelium 
in a P-selectin-dependent manner and produce thrombogenic 
tissue factor (TF) in the IVC stenosis model (17). TF, then con-
tributes to thrombin generation and extensive fibrin deposition 
along the vein wall. Despite this finding, TF alone was inadequate 
for thrombus propagation. Neutropenia, genetic ablation of 
Factor XII, and disintegration of NETs were all protective against 
thrombus propagation. Later, activated PMNs within the fibrin 
matrix were found to produce NETs that associate with secreted 
Factor XII, activate the intrinsic pathway, and lead to thrombus 
extension (17, 21). However, these conclusions were questioned, 
as during the same year, TF was also found to be secreted by 
PMNs in an inflammatory signaling and autophagy-dependent 
manner, with adherence to extruded NETs, activation of the 
extrinsic pathway, and eventual propagation of the thrombus 
(18, 22). Regardless, the presence of PMNs and/or monocytes at 
the endothelial interface has long been assumed to have a major 
role in VT and now appears unquestionable (17, 18, 23, 24).
Many proteins have been implicated in contributing to 
NETosis and thrombosis. In 2013, Martinod et al. demonstrated 
that the enzyme peptidyl arginine deiminase 4 (PAD4)  –  an 
enzyme essential for the citrullination and decondensation of 
chromatin was – not only essential for NET formation but also 
important for thrombus formation in the IVC stenosis model 
of murine VT (25). PAD4−/− mice formed IVC thrombus in 
less than 10% of cases of IVC stenosis at 48 h compared to 90% 
in C57BL/6 controls (25). This antithrombotic tendency was 
rescued in the PAD4−/− mice with adoptive transfer of wild-
type PMNs. Conversely, in a stasis IVC ligation model of VT, 
either preemptive administration of DNase to wild-type mice or 
PAD4−/− mice did not have an effect on thrombogenesis, suggest-
ing a model-dependent effect (19).
Other proteins that have been implicated in NET formation 
and NET-associated thrombosis include cathepsin G, serine 
proteases, PMN elastase, P-selectin, high-mobility group box 
protein 1 (HMGB-1), platelet glycoprotein Ib, integrin beta-2, 
vWF, and platelet factor 4. Pharmacological inhibition or genetic 
deletion of cathepsin G increases mouse bleeding time, decreases 
platelet activation, and decreases circulating neutrophil–platelet 
conjugates (26). While the serine proteases and PMN elastase 
have been implicated in pathologic thrombosis and have been 
found to colocalize with NETs (27), it was recently demonstrated 
that PMN elastase is neither necessary for NET formation in 
mice nor essential for IVC thrombosis in murine IVC stenosis 
model (28). Indeed, it is likely that the prothrombotic effect of 
the serine proteases is better explained by their inhibition of 
tissue factor pathway inhibitor (TFPI) (29). Signaling through 
P-selectin by P-selectin glycoprotein ligand 1 (PSGL-1) is known 
to assist in PMN migration to sites of injury or inflammation 
(30), but beyond that, the P-selectin axis has now been postu-
lated to promote NETosis in the setting of activated platelets 
(24). However, this conclusion was recently challenged in a study 
that demonstrated that HMGB-1 expressed by activated platelets 
was individually capable of activating PMNs via the receptor for 
advanced glycosylation end-products (RAGE) to induce NETosis 
(31). Similarly, in 2016, an in vitro study demonstrated activated 
platelets binding to vWF through glycoprotein Ib, in turn, linked 
to PMNs via integrin beta-2 and stimulated by platelet factor 4 led 
to NETosis independent of P-selectin (32). While our knowledge 
of NET formation continues to grow, the specific proteomic 
cascade that leads to NETosis remains contested. These findings 
also underline the heterogeneity and limitations of model systems 
as well.
Given that thrombi consist of significant quantities of DNA 
combined with proteins, thrombosis resolution and associated 
inflammation becomes less straight forward. We have explored 
this topic in our laboratory by examining toll-like receptor 9 
(TLR9) function in VT resolution. TLR9 is a conserved pathogen-
associated molecular pattern (PAMP) and damage-associated 
molecular pattern (DAMP) receptor that recognizes CpG DNA 
repeats and alerts the immune system to invading pathogens or 
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local damage. In an IVC ligation model of VT (complete stasis), 
TLR9−/− mice had significantly increased thrombus size at 2 
and 8 days despite increased numbers of PMNs and monocyte/
macrophages (33). Further, TLR9−/− mice had increased apop-
tosis, citrullinated histones, PAD4, and neutrophil elastase; and 
reduced TFPI (19), suggesting that TLR9 is important for normal 
thrombogenesis and thrombosis resolution. Lastly, M1-like 
(CCR2+) monocyte/macrophages were decreased in TLR9−/− 
thrombi, consistent with impaired inflammatory cell influx, and 
this divergence was corrected with adoptive transfer of TLR9+/+ 
bone marrow-derived monocytes with normalization of throm-
bus size (20). The new found composition of DNA-rich thrombi 
will likely have long-standing implications for future research in 
VT resolution.
NeTs iN PRiMATe AND  
HUMAN vT STUDieS
Although first thought to only occur in pathologic states, NETosis 
with release of extracellular DNA has been shown to occur in 
healthy individuals (34). Following exhaustive treadmill or cycling 
exercise, circulating levels of cell-free DNA (cfDNA) and myelop-
eroxidase (MPO) rise, and isolated PMNs from the circulation 
develop swollen nuclei and emanating DNA. A concomitant rise 
in circulating DNase occurs, suggesting that similar to the ongo-
ing processes of fibrin formation and fibrinolysis, NETosis may be 
a tightly regulated and constantly ongoing homeostatic process. 
Dysregulation of NETosis and its relationship to thrombosis 
has been recognized in a variety of clinical scenarios: NETs are 
present in fresh thrombi from individuals with acute myocardial 
infarction (31, 35), they are found in high circulating levels in 
patients with severe trauma and microvascular thrombosis with 
acute lung injury (6); and in patients with thrombotic microan-
giopathies (TMAs) (8). Circulating cfDNA rises 24 h following 
chemotherapy in breast cancer patients, corresponding to peak 
in thrombin–antithrombin levels (36). This has been proposed as 
a potential causative mechanism for the high rate of thrombotic 
events experienced by individuals undergoing chemotherapy.
Ex vivo platelet activation studies with recombinant human 
histones demonstrate that not all histones are created equal in 
NETosis: only histone 3 (H3) and histone 4 (H4) induce func-
tional platelet response (37). Recent advances in techniques of 
PMN isolation (38) and recognition of NETs in human pathologic 
thrombus specimens have improved the ability to study NETosis 
in humans (39).
The link between human venous thromboembolism (VTE) 
events and NETosis has been established in a handful of studies 
to date. Analysis of balloon occlusion-induced iliac thrombosis 
in a baboon model of VT demonstrated increased circulating 
NETs at 48  h post-thrombosis and persisting through 6  days 
(3). Consistently, extracellular DNA markers were present in 
the experimental thrombus. In 2013, a human study composed 
of healthy controls and symptomatic patients (swelling and leg 
pain) with and without VT examined circulating NET markers 
(40). Extracellular DNA and MPO were significantly elevated 
in symptomatic patients with VT compared to both groups of 
non-thrombosed patients. A direct correlation was also seen 
between common predictors of thrombosis including D-dimer, 
Wells score, and plasma DNA, suggesting that NETs may be 
useful in diagnostic evaluation. Development of more accurate 
methods to diagnose VT is of particular interest as the current 
“gold standard,” duplex ultrasound, is often limited in availabil-
ity and in evaluation of central veins (41). In the same year, a 
similar case–control study of 195 individuals with and without 
VT examined nucleosomes and α-1 antitrypsin elastase (as a 
PMN activation marker) in relation to thrombosis. Levels of 
nucleosomes and PMN activation above the 80th percentile were 
associated with a threefold risk of VT (42).
The precise role of NETs in VT initiation, formation, and 
propagation, as well as optimal area to intervene in human VT 
remains relatively unknown. In a study evaluating unorganized, 
organizing, and organized thrombi from patients with either VT 
or PE, CD11b, and MPO positive cells were seen in organizing 
thrombi along with intra- and extracellular CitH3 and PAD4 (43). 
Unorganized and organized thrombi failed to demonstrate the 
similar histopathology, suggesting the predominant role of NETs 
during the inflammatory response and thrombus organization 
(43). Another study of 29 VT patients and controls demonstrated 
increased neutrophil adhesion and inflammatory cytokine pro-
file among patients with residual vein obstruction and elevated 
D-dimer (44). Ex vivo studies of NETs related hypercoagulability 
in inflammatory bowel disease (IBD), and TMA patients have 
demonstrated efficacy of DNAse I in decreasing the thrombotic 
response, although this has yet to be shown in human VT 
(11, 12). To date, no clinical trial has targeted NETs in humans as 
a mechanism to prevent or treat VT.
NeTs iN iMMUNOTHROMBOSiS
While the ability to form thrombus in the face of vessel injury 
has long been known to be essential for the maintenance of 
hemostasis, until recently, it had not been recognized as an 
intravascular mechanism of immune defense. Engelmann and 
Massberg recently reviewed the mechanism of NET-mediated 
microvascular thrombosis and proposed it as a potential bio-
logical adjunct for containing uncontrolled infection, coining this 
process “Immunothrombosis” (45). In their review of the topic, 
they proposed four mechanisms by which immunothrombosis 
prevents the spread of infection (1) it captures and ensnares 
pathogens in the microvasculature and prevents dissemination, 
(2) it prevents distant tissue invasion by forming microthrombi 
in microvessels, (3) it concentrates pathogens in one area for 
bactericidal killing by innate immune cells, and (4) it recruits 
other immune cells to the site of inflammation for further bacte-
rial killing. Indeed, coagulation has been previously postulated 
to play a role in host defense against bacteria (46, 47), but if left 
unchecked, immunothrombosis may contribute to significant 
systemic pathology.
Severe sepsis accounts for 10–40% of ICU admissions in 
the United States and carries a mortality rate of 20–50% (48, 
49). NET-related immunothrombosis, cfDNA, and histones 
have been implicated in the morbidity and mortality of sepsis. 
In in vitro and in vivo models of sepsis, LPS has been shown to 
activate platelets and PMNs via toll-like receptor 4 (TLR4) to 
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induce NETosis (31, 50, 51). Intravascular NETs can be digested 
by DNase to release cfDNA and histones, and further, cfDNA 
obtained from human specimens has been shown to be at 
~150–300 bp sizes consistent with nucleosome units (52). In the 
same study, cfDNA levels in peripheral blood of patients with 
severe sepsis were found to be highly predictive of ICU mortality. 
In 2009, Xu et  al. demonstrated that extracellular histones led 
to endothelial dysfunction, organ failure, and death in animal 
models of sepsis (4). Specifically, histone administration to mice 
resulted in neutrophil activation, endothelial toxicity, acute lung 
injury, and microvascular thrombosis. Interestingly, antihistone 
antibodies and activated protein C (APC) improved mortality 
rates in sepsis models in these mice. In addition, NETosis has also 
been linked to prothrombotic activity because NET-associated 
enzymes break down TFPI (29), while also enhancing antifi-
brinolytic activity because cfDNA inhibits plasmin-mediated 
fibrin degradation (13, 14, 28). Further, H3 levels were found to 
correlate with ICU mortality and were inversely correlated with 
antithrombin and platelet levels (53). Structurally, NET-induced 
immunothrombosis leads to more sturdy thrombi with less 
permeability and decreased susceptibility to lysis, although this 
may be overcome with DNase (54). In a murine cecal ligation and 
puncture model of sepsis (CLP), DNase given at 6 h after injury 
reduced organ damage and mortality (55). Lastly, bacterial resist-
ance to NET trapping has been demonstrated in  vitro and has 
been postulated to contribute to widespread immunothrombosis 
in the septic host leading to disseminated intravascular coagula-
tion (DIC) (56, 57).
In addition to its inflammatory role in sepsis, NETs and 
immunothrombosis have also been implicated in autoimmune 
disease. Phosphatidylserine (PS) and TF-bearing microparti-
cles (MP) were found to be markedly increased in the sera of 
IBD patients (11). Increased TF-bearing MPs correlated with 
increased NETosis, markedly shortened coagulation times, and 
increased levels of fibrin, thrombin, and factor Xa. Similarly, in an 
in vitro study of antineutrophil cytoplasmic antibody-associated 
vasculitis (ANCA-AV or AAV), C5a-primed PMNs treated with 
ANCA IgG-released NETs and TF-bearing MPs contributing to 
a prothrombotic state, and interestingly, this was remedied par-
tially by DNase treatment (58). TMAs, more commonly known as 
thrombotic thrombocytopenic purpura (TTP), hemolytic uremic 
syndrome (HUS), and DIC, are characterized by microvascular 
thrombosis and coagulopathy. In vitro studies of TMAs demon-
strate that the sera of TMA patients are incapable of degrading 
NETs due to a deficiency of DNase I and this may contribute to 
widespread microvascular thrombosis and organ dysfunction 
(12). Intriguingly, supplementation of TMA sera with recombi-
nant human DNase I reestablished NET degradation capability. 
Lastly, PMNs from patients with antiphospholipid antibody 
syndrome (APS) were inclined for spontaneous NETosis and 
thrombin generation, and further, APS sera and APS-isolated 
IgG stimulated NETosis in control PMNs (59). These findings 
highlight the prothrombotic role of NETs in autoimmune-related 
immunothrombosis.
Finally, NETs have also been implicated in multiple organ 
failure related to severe trauma. In 2013, Abrams et al. examined 
a cohort of 52 patients with severe non-thoracic blunt trauma 
and correlated circulating histone levels with acute lung injury 
and sequential organ failure assessment scores (SOFA) (6). 
Circulating histone levels increased dramatically immediately 
following trauma and high levels correlated with acute lung injury, 
SOFA scores, endothelial injury, and coagulation activation. In 
the same study, with translational animal models of blunt trauma, 
circulating histone levels corresponded with organ edema, hem-
orrhage, microvascular thrombosis, and neutrophil congestion. 
Multiple organ dysfunction syndrome (MODS) is a leading 
cause of delayed mortality following major trauma and has been 
correlated with circulating cfDNA levels (52). Inherently, future 
research should look to address NETosis and immunothrombosis 
as potential therapeutic targets for preventing immune-mediated 
MODS after severe injury.
SUMMARY, iNTeGRATiON, AND 
POTeNTiAL TRANSLATiON
Over the past 12  years, since its discovery, NETosis has been 
catapulted to the forefront of innate immunity research. Nowhere 
is its effect more relevant in human disease than in its implica-
tion in immune-mediated micro- and macrovascular thrombosis 
(Figure 1). In this review and others, NETs have been shown to 
have a significant role in pathogenic thrombosis through platelet 
and PMN recruitment to the endothelial wall, subsequent activa-
tion and NETosis, and proteomic activation of the intrinsic and 
extrinsic coagulation cascades, ultimately leading to thrombosis 
(3, 13, 14, 16, 17, 31, 32, 45, 50, 60, 61).
This unique development in the etiology of immune-mediated 
thrombosis affords novel targets for the prevention of pathologic 
thrombosis in a susceptible patient (Table 1) (4, 25, 55, 62–70). 
One obvious target for the prevention of NET-mediated VTE is 
PAD4 inhibition (25, 60). Enzymatic inhibition of PAD4 would 
prevent NETosis, and hopefully, its prothrombotic effects as well; 
however, this may also leave the host susceptible to bacterial 
infection (71). DAMP-mediated NETosis by HMGB-1 is also 
a potential therapeutic target. HMGB-1 is released from dam-
aged cells and expressed on the surface of activated platelets and 
leads to immune system activation via RAGE, TLR2, and TLR4 
(5, 72, 73). HMGB-1-mediated PMN activation subsequently 
contributes to microvascular thrombosis and NETosis (31, 74). 
HMGB-1 is cleaved by thrombomodulin–thrombin complexes 
in vivo, and recombinant thrombomodulin is presently approved 
for the treatment of DIC in Japan and is in phase III trials here in 
the United States (5, 70).
Other targets include the components of PMN and platelet 
recruitment to the endothelium. Specifically, blockade of plate-
let alpha-granule release or endothelial Weibel–Palade body 
release would decrease P-selectin and vWF-mediated platelet 
and PMN recruitment to the endothelium decreasing NETosis 
(24, 32, 75, 76). Similarly, blockade of P-selectin (24), vWF A1 
domain (16), glycoprotein Ib, or integrin beta-2 may reach a 
similar end, however, more specifically (32). Lastly, the vWF 
degradation enzyme, ADAMTS13 (a disintegrin and metallopro-
teinase with thrombospondin type 1 motif – member 13), may 
TABLe 1 | Targets for translation in the prevention of NeT-mediated 
thrombosis (4, 25, 55, 62–70).
Scenario Target Treatment
Sepsis thrombotic 
microangiopathies
Histones
Antihistone Antibodies  
Activated protein C
cfDNA DNAse
Endothelial activation 
and thrombosis (stasis, 
endothelial injury, 
coagulopathy, sepsis, 
trauma, and transplant 
rejection)
Weibel–Palade body 
release
Inducers of inducible nitrous 
oxide synthase (iNOS)
Platelet α-granule 
release
Aspirin and clopidogrel 
thromboxane A2 inhibitors
vWF rADAMTS13
vWF Al domain vWF Al domain aptamer
Glycoprotein Ib Inhibitors of glycoprotein 
Ib–vWF interaction
Integrin β2 Inhibitors of integrin β2–vWF 
interaction
P-selectin P-selectin inhibitors and 
clopidogrel
HMGB-1 Thrombomodulin
PAD4 PAD4 inhibitors
FiGURe 1 | Diagram of theoretical mechanism of NeT-mediated 
microvascular thrombosis in sepsis. (A) Sepsis-induced endothelial 
activation leading to the release of vWF (black lines) from endothelial cell 
Weibel–Palade bodies provoking the recruitment of leukocytes and platelets 
to the endothelial wall via vWF A1 domain–beta-2 integrin interaction (vWF–
PMN interaction; orange diamond) and vWF A1 domain–glycoprotein Ib 
interaction (vWF–platelet interaction; green diamond). PMNs are also 
recruited to the endothelium via P-selectin-to-PSGL-1 interaction (black 
diamond) inducing neutrophil rolling. (B) Neutrophil and platelet activation by 
LPS (yellow triangle) via TLR4 (blue triangle). Platelet activation leading to the 
release of PF4 (blue square) and expression of P-selectin (black diamond) 
and HMGB-1 (pink diamond) further stimulate NETosis [purple lines of 
decondensed chromatin with attached histones (yellow circles)]. NETosis also 
leads to autophagy-induced release of TF, and NETs further stimulate FXII 
activation, inciting both the intrinsic and extrinsic coagulation cascades. 
(C) Thrombin activation by factor Xa leads to the conversion of fibrinogen to 
fibrin (yellow lines) culminating in microvascular thrombosis.
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be given in a recombinant form (rADAMTS13) to degrade vWF 
and prevent PMN recruitment with subsequent NETosis (77). 
Although, each of the above-listed countermeasures may result 
in mild immunodeficiency, if given in a dose-dependent manner, 
they may abrogate the pathologic immune-mediated thrombosis 
without sacrificing immune competence.
Despite the relatively recent discovery of NETs as a con-
tributor to VTE, some long-standing traditional VTE therapies 
already affect NETs. Polyanionic heparin, long considered the 
gold standard therapy for prevention and treatment of VTE, 
has a secondary effect of displacing histones from chromatin 
(78, 79). This allows increased accessibility of nucleases to the 
exposed chromatin, further permitting degradation of NETs 
(78, 79). Similarly, aspirin, recently shown to decrease risk of 
recurrent VTE (80), inhibits NETosis in vitro by inhibition of 
thromboxane A2 synthesis (63, 81). Finally, clopidogrel has also 
been shown to decrease inflammation and platelet-mediated 
expression of soluble P-selectin, further decreasing PMN–
platelet interactions and hence NETosis (68). It is currently 
unknown as to the effects of the new oral anticoagulants on 
NETs, although this may represent an important area for future 
investigation.
Thrombolysis has become a key weapon in the arsenal against 
pathologic thrombosis; however, not all thrombotic events are 
susceptible to thrombolysis with tissue plasminogen activator 
(tPA) (82). Indeed, the addition of DNA and histones to a fibrin 
matrix has been shown to make artificial thrombus more stable, 
more rigid, and more resistant to tPA, and this is partially rem-
edied by DNase (83). Preliminary data from murine models of 
VT demonstrate inhibition of thrombus formation with DNase 
instillation prior to and during IVC stenosis (16, 17). In another 
study of limb ischemia-reperfusion injury, DNase instillation 
decreased tissue NETs but did not effect end tissue damage or 
inflammatory infiltrate (84). In spite of this, more recent studies 
have shown decreased inflammation, increased tissue perfusion, 
and improved survival with (1) late DNase treatment in cecal liga-
tion puncture (CLP) model of murine sepsis (55), (2) concurrent 
DNase and tPA treatment in a rat model of myocardial ischemia 
6Kimball et al. NETs and Thrombosis
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(85), and (3) preemptive DNase treatment in a rat model of renal 
ischemia-reperfusion injury (86). Combination tPA and DNase 
therapy for thrombolysis of acute ischemic events has yet to be 
studied in human patients but will likely constitute a major area 
of research in the near future.
There are still many unanswered questions in the field of 
NETosis. What are the exact proteomic mechanisms that lead to 
neutrophil activation and subsequent NET formation? What is 
the role or RAGE, and does this have implications for diabetics? 
What is the intracellular cascade that leads to PAD4 induc-
tion? After NETosis and thrombosis, how are NETs naturally 
removed from the resolving thrombus? Do NETs play a role in 
the post-thrombotic syndrome? Will the addition of DNase to 
tPA broaden the spectrum of patients that can be treated with 
thrombolysis as opposed to surgery? These questions and more 
will be answered with time and continued diligent, meticulous, 
and conscientious research. We look forward to the future with 
great expectations for upcoming discoveries in the field of 
NETosis.
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